This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
The Florida MedSpa deal is the transaction most likely to die on a topic nobody negotiated. The buyer — a non-physician PE sponsor, a family office, or a strategic aggregator building a regional platform — signs an LOI at a multiple that assumes the transaction closes as a straightforward asset or stock purchase. The seller, a nurse practitioner or aesthetician who has built a beautiful cash-flowing practice over the last decade, signs on the same assumption. Then the buyer’s deal counsel runs the corporate-practice-of-medicine analysis and the deal reshapes itself overnight. The buyer discovers it cannot own the professional entity that actually delivers the injectables and the laser services. The seller discovers that the ownership structure she assumed was standard is a regulatory patchwork held together by a supervising physician who was rarely on site. The deal does not necessarily die — but it becomes an MSO transaction, priced differently, structured differently, and closed on a different timeline. Everything below is doctrinal and hypothetical.
The corporate-practice-of-medicine doctrine in Florida
Florida’s corporate-practice-of-medicine doctrine is not codified in a single statute the way it is in some other states. It emerges from the interaction between the Florida Medical Practice Act (Chapter 458 for allopathic physicians and Chapter 459 for osteopaths), the professional-service-corporation statute in Chapter 621, the fee-splitting prohibition in FL § 458.331(1)(i), and a body of Board of Medicine and Department of Health guidance built up over years of disciplinary decisions. The doctrine, stitched together, means the same thing the CPOM doctrine means in the majority of states: a corporate entity that is not owned by licensed physicians cannot practice medicine, cannot employ physicians to practice medicine, and cannot control the physician’s clinical judgment. The Department of Health enforces this by reference to Chapter 458 and by administrative rule.
What makes MedSpa deals interesting is that the services offered by a modern MedSpa — neurotoxin injections, dermal fillers, laser hair removal, IPL, microneedling with topical anesthetic, PDO threads, PRP, RF microneedling, some weight-loss injectables — are almost all categorized by the Florida Board of Medicine as the practice of medicine. The Board’s position on injectables in particular is that the initial patient examination, the diagnosis, and the treatment plan are physician functions, delegable to a nurse practitioner or physician assistant only under a valid protocol and only within scope. A non-physician cannot own the professional entity that renders those services. That single fact drives the entire structure of the deal.
Why the MSO structure is the answer — and how it actually works
The management-services-organization structure is the response the private-equity industry developed to the corporate-practice-of-medicine doctrine, first in dermatology and ophthalmology roll-ups in the mid-2010s, and now in MedSpa, dental, veterinary, and every other clinician-driven category. The structure has two entities. The professional entity — typically a Florida PA or PLLC owned by a licensed physician — owns the medical practice and employs the clinicians who render the professional services. The MSO — a separate LLC that can be owned by anyone, including the PE sponsor — owns everything else: the lease, the equipment, the front-office and back-office employees, the software, the marketing spend, the accounts receivable to the extent permitted, and the intellectual property. The two entities enter into a long-term management services agreement under which the MSO provides all non-clinical services to the professional entity in exchange for a management fee.
The economic reality is that most of the enterprise value sits in the MSO. The professional entity retains the physician’s clinical judgment and the professional license. The management fee is calibrated so that after paying it, the professional entity has just enough left over to pay clinician compensation and reasonable owner distributions to the physician-owner. That calibration is not arbitrary. Under FL § 458.331(1)(i)’s fee-splitting prohibition, the management fee cannot be a percentage of professional revenues in a way that operates as fee-splitting. The safer approach is either a fixed monthly fee tied to fair market value, or a cost-plus-reasonable-margin methodology supported by an FMV opinion. Where the deal is large enough to warrant it, that opinion is done at closing and refreshed periodically.
Layered on top of the MSO/PC structure is the friendly-PC arrangement that gives the sponsor practical control without regulatory ownership. The physician-owner enters into a stock transfer restriction agreement with the MSO that gives the MSO the right to designate the successor physician-owner on triggering events — the physician’s death, disability, retirement, license revocation, or breach. The MSO holds a security interest in the physician-owner’s equity to secure the restriction. Combined with the management agreement and a long-term physician employment agreement, the structure gives the sponsor economic exposure to the practice’s upside while leaving formal ownership with the physician. The Board of Medicine and DOH have not blessed the structure in a written opinion, but they have not condemned it either, and it is the model on which essentially every physician-practice roll-up in Florida is built. That framing is closely related to what I wrote in the founder commentary on a PE stockholders agreement post.
What actually gets diligenced in a MedSpa deal
The diligence stack for a Florida MedSpa transaction has a set of items that do not appear in a general business-services deal. The first is the supervising physician relationship. Most non-physician-owned MedSpas operating in Florida do so under a medical director agreement with a licensed physician who supervises the ARNPs and PAs providing injectables. The agreement is typically a monthly retainer for a defined number of hours of supervision per week or month. What buyers find in diligence, over and over, is that the medical director is a physician the seller has retained on a shoestring, that the physician has never actually seen most of the patients, and that the supervising protocols and standing orders required under FL Board of Nursing Rule 64B9-4 have not been consistently followed. A buyer’s response is either to require the seller to remediate before closing, to negotiate a specific indemnity for pre-closing supervision violations, or to renegotiate the price to reflect the risk.
The second is the informed-consent and treatment-record file. Florida requires that each patient sign an informed consent for each treatment, that the physician-directed treatment plan be documented, and that the records be maintained for a defined period. A buyer sampling a hundred patient charts and finding that a third are missing consents or lack a documented treatment plan has identified both a regulatory exposure and a valuation problem. The third is the standing-order and protocol file — the written protocols under which ARNPs and PAs administer injectables and lasers. Fourth is the DEA and prescription drug purchase file, especially for practices that stock or dispense weight-loss injectables or lidocaine for topical use. Fifth is DOH inspection history and any open complaints or investigations. Sixth is the employment-agreement file for the clinicians — the non-competes, the assignment provisions, and any bonus structures that could be recharacterized as fee-splitting.
A separate diligence strand is device leases and manufacturer relationships. High-end MedSpas own or lease laser and RF platforms; the equipment cost is meaningful and the manufacturer service agreements often carry change-of-control clauses. A buyer who has not confirmed assignability can inherit a fleet of six-figure devices with no warranty coverage and no manufacturer support.
Deal structure — asset, stock, or friendly-PC recapitalization
The deal-structure choice in a Florida MedSpa transaction is more constrained than in a general business services deal. A pure stock purchase of the professional entity by a non-physician sponsor is not available — the sponsor cannot own the PA or PLLC. A pure asset purchase is available in theory but often defeats the deal’s tax objectives for the seller and creates transition issues around the professional license, the DEA number, the office lease, and the practice’s tax-ID-linked contracts. The structure most commonly used is a hybrid: the MSO acquires the non-clinical assets of the practice in an asset purchase, a new professional entity is formed and owned by a physician-owner acceptable to the sponsor (or the existing physician-owner continues, with a new stock transfer restriction), the new professional entity assumes the clinical business, and the two entities enter into the management services agreement. The selling physician or non-physician owner receives a mix of cash and MSO equity, and rolls into the platform.
For the mechanics of that split, the asset-vs-stock framework I’ve written about applies with some MedSpa-specific overlays. The lease assignment, the software vendor consents, the manufacturer service agreements, and the DEA-registration transfer all require attention that a generic services-deal checklist does not surface. The corporate structure of the resulting platform is what determines both the closing timeline and the tax treatment of the rollover, so getting it right at the LOI stage is worth the extra week of work up front. The broader deal-terms framing is in the seller-friendly vs. buyer-friendly deal terms post.
The non-compete question and clinician retention
The non-compete in a MedSpa deal has two audiences. The first is the selling owner — standard practice is a five-to-seven-year non-compete tied to the sale, enforceable under FL § 542.335 as a restriction ancillary to the sale of a business. The second is the clinician non-competes — the ARNPs, PAs, and aestheticians who actually generate the revenue. Florida’s enforceability standard for employee non-competes is more restrictive than for sale non-competes, and the enforceability against ARNPs in particular has faced pressure both from federal-level activity around non-compete restrictions and from the practical reality that a MedSpa without its injector loses its book of business overnight. Buyers who are underwriting a MedSpa deal at a healthy multiple are relying on continuity of the clinicians, and the diligence question — how enforceable are the existing non-competes, and if the answer is “not very,” what retention economics are needed to hold the team through the earnout period — is central to the price. That interacts closely with the M&A practice framing at the M&A page.
DOH oversight and the closing-week checklist
The Department of Health does not have a change-of-ownership approval process for medical practices the way AHCA does for licensed health-care facilities. But DOH still touches the transaction at multiple points. The physician-owner’s Chapter 458 license must remain in good standing. Any office-surgery registrations under FL § 458.328 (for practices performing Level II or III office surgery) require re-registration on ownership change. Prescription-drug-related licenses and permits — both DEA and Florida DOH — run on the professional entity’s tax ID and require attention when a new PA is formed. The transition-services agreement between the seller and the buyer typically covers a defined post-closing period during which prescription-writing authority, billing, and records access are stabilized. For the underlying statutory framework, the Florida Senate maintains online.
The closing-week checklist runs longer than a typical services deal. The new professional entity has to be formed at Sunbiz, DEA registration issued or transferred, the office-surgery re-registration filed if applicable, the medical director agreement executed, standing orders re-adopted, manufacturer service agreements assigned, lease assigned, software vendor contracts assigned, and payroll transitioned. Parties who do this work carefully close on schedule. Parties who treat it as a generic services deal end up with a six-week delay and an unhappy physician-owner.
Florida MedSpa M&A is a good deal segment. The unit economics are strong, the roll-up thesis is real, and the seller pool skews toward first-time sellers who have built genuinely good businesses. What kills these deals is not the price. It is the structure. A buyer who understands the corporate-practice-of-medicine doctrine, has the MSO template ready, and runs the supervising-physician diligence before signing the LOI closes on time. A buyer who treats a MedSpa like a general services business does not.
If you are a MedSpa founder considering a sale, or a sponsor evaluating a Florida platform, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
— John
